ArticleEuropean heart journal open2026
Clinical implications and recurrence rates of first-time catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a nationwide cohort study.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Catheter ablation (CA) for atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM) poses unique challenges due to structural and electrical remodelling. This study examines AF recurrence and complication rates following CA in HCM patients compared to a matched AF non-HCM cohort. Methods and results: A retrospective cohort study of Danish nationwide registries from 2010 to 2022 was conducted. Rates of AF recurrence, heart failure, ischaemic stroke, and death were analysed using propensity score matching and Cox regression models. Among 28 231 patients undergoing first-time CA for AF, 299 had a confirmed diagnosis of HCM. Patients with HCM demonstrated significantly higher rates of AF recurrence compared to a matched non-HCM cohort, with 40% experiencing recurrence vs. 30% in the non-HCM group after 1 year and 67% vs. 58% after 5 years [hazard ratio (HR) 1.41, Conclusion: HCM patients experience higher AF recurrence rates post-CA as well as a higher risk of heart failure. These findings highlight the need for tailored strategies to improve outcomes in this high-risk group.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.